Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study
Matthaei, Stephan × Reaney, Matthew Mathieu, Chantal Ostenson, Claes-Göran Krarup, Thure Guerci, Bruno Kiljanski, Jacek Petto, Helmut Bruhn, David Theodorakis, Michael #
Springer Healthcare Ltd.
Diabetes Therapy vol:3 issue:1 pages:6
Changes to Treatment and Outcomes in Patients with Type 2 Diabetes Initiating Injectable Therapy (CHOICE) is a European prospective, observational cohort study assessing time to, and factors associated with, a significant change in therapy after type 2 diabetes patients initiate their first injectable glucose-lowering therapy, and these patients' clinical outcomes over 24 months. The authors report baseline data and factors associated with the injectable treatment regimen.